Biocon Ltd News

Biocon spurts 3% as Pertuzumab drug moves closer to marketing nod in Europe

Biocon jumped nearly 3% in Monday's trade after the company's Pertuzumab biosimilar drug received EMA CHMP recommendation for breast cancer care.

Biocon share price rises 3% after block deal, Pertuzumab deal in Brazil

According to data compiled by Bloomberg, around 16.6 million shares of Biocon changed hands on the BSE in a single pre-market block trade.

Stocks to watch: Sun Pharma, Suzlon Energy, OMCs, Biocon, IHCL, Tata Power

Stocks to watch: Sun Pharma, Suzlon Energy, OMCs, Biocon, IHCL, Tata Power, TCS, Jio Financial Services, HCL Technologies, Emami Ltd, Bajaj Finance, among others, will be in focus today.

Stocks to watch: Swiggy, Manipal Health, Biocon, RailTel, Sammaan Capital

Stocks to watch today: Swiggy, Manipal Health, Biocon, L&T Finance, Crompton Greaves, RailTel Corporation, Sammaan Capital, EaseMyTrip, among others, will be in focus today.

Biocon eyes stronger H2FY27 growth on back of recent US product launches

Biocon expects momentum to strengthen in H2FY27, driven by new US biosimilar and generic launches, improved operating leverage and a favourable product mix

Q1 results today: Aurobindo Pharma, Biocon, PB Fintech, 130 more on Aug 5

Q1FY27 company results: Firms including JK Lakshmi Cement, Power Grid Corporation of India, Berger Paints, and Bikaji Foods are also to release their April-June earnings today

Biocon gets Canadian health regulator's nod for Yesintek autoinjector pen

: Biocon Ltd on Wednesday said it has received notice of compliance approval from Canadian health regulator for its Yesintek (ustekinumab) autoinjector, indicated for the treatment of moderate to severe plaque psoriasis. The company's subsidiary in Canada has received Notice of Compliance (NOC) approval for Yesintek (ustekinumab) Autoinjector 45 mg/0.05 mL and 90 mg/mL from Health Canada, Biocon Ltd said in a regulatory filing. Health Canada previously granted NOC for Yesintek (solution for subcutaneous injection) 45 mg/0.5ml (prefilled syringe and vial) and 90 mg/ml (prefilled syringe) and Yesintek I.V. (solution for intravenous infusion) 130 mg/26 mL (5mg/mL) in October 2025, it added. The availability of the Yesintek autoinjector provides patients with an option that the originator product does not offer in Canada, the company said . The new format will allow customised treatment approaches across care settings and patient needs, it added. Biocon said Yesintek is indicated for

Biocon gains 3%, stock nears record high; should you buy, hold or sell?

Biocon received approval from the European Medicines Agency (EMA) for a new drug product fill finish line for Semglee (insulin glargine) at its insulin manufacturing facility in Malaysia.

Biocon surges 6%, nears 52-week high after block deals; Mylan likely seller

According to reports, Mylan, which is part of Viatris, planned to sell up to 5.64 per cent stake in Biocon, worth up to ₹3,481 crore in block deals today.

Stocks to Watch today: HCL Tech, Asian Paints, PC Jewellers, Biocon & more

Gift Nifty futures were trading 168 points or 0.69 per cent lower at 24,050 levels, signalling a gap-down start. Meanwhile, shares of HCL Tech, Asian Paints and Biocon will be in focus today.

Viatris unit Mylan plans to sell stake worth up to $363 million in Biocon

Mylan, part of global healthcare company Viatris, plans to sell up to 92 million shares in Biocon through a secondary offering valued at as much as Rs 34.81 billion

Stocks to Watch today: HDFC Bank, Biocon, SJVN, Container Corp, Yes Bank

Stocks to Watch today, June 30, 2026: Tech Mahindra, Axis Bank, Godrej Properties, RITES, SIS, Jagsonpal Pharma, and Sterling and Wilson Renewable Energy are top stocks to remain in focus

Nifty Pharma extends rally, up 2%; Piramal Pharma, Laurus gain up to 10%

Analysts said that a combination of defensive buying, strong earnings visibility, export tailwinds, and sector rotation is driving the rally in pharma stocks.

Biocon's next chapter: A leadership team built for the next decade

The team put together by the firm's founder may be just what the next decade demands

Biocon soars 10% in 3 days, stock nears 52-week high; here's why

In the past 12 trading days, the market price of Biocon has appreciated by 20 per cent from a level of ₹349.65 on the BSE on April 24, 2026.

Nifty, Bank Nifty strategy; 3 stock recommendations by Motilal Oswal

Chandan Taparia of Motilal Oswal decodes how to trade Nifty and Bank Nifty today; here are stock bets and strategy

Claire has what it takes to lead Biocon forward: Kiran Mazumdar-Shaw

Kiran Mazumdar-Shaw explained why she has chosen her niece, Claire, as her successor, outlining a five-year transition plan that will eventually see Claire take over as chairperson

Biocon eyes in-licensing opportunities to expand biosimilars portfolio

Biocon is scouting for biosimilar in-licensing opportunities while banking on multiple FY27 product launches to drive growth, margins, and market expansion

Biocon shares gain 3% despite 57% drop in Q4 profit; dividend announced

Bengaluru-based Biocon said that its Q4 profit stood at ₹198.6. The profit was hit by an exceptional item outgo of ₹80.4 crore on various heads, including the impact of the new labour code.

Biocon Q4 result: Profit down 56.8% at ₹198.6 cr; revenue at ₹4,516.6 cr

Biocon Ltd has reported a 56.8 per cent decline in consolidated net profit at Rs 198.6 crore in the fourth quarter ended March 31, hit by exceptional item outgo of Rs 80.4 crore on various heads, including impact of new labour code. The company had posted a consolidated net profit of Rs 459.4 crore in the corresponding period previous fiscal, Biocon Ltd said in a regulatory filing on Thursday. Consolidated revenue from operations in the fourth quarter was at Rs 4,516.6 crore as against Rs 4,417 crore in the year-ago period, it added. Total expenses in the fourth quarter were higher at Rs 4,241.2 crore as compared to Rs 3,987.5 crore in the same period a year ago, it said. The company's board has recommended a final dividend of 50 paise per equity share of face value of Rs 5 each for the financial year ended March 31, 2026, subject to shareholders' approval at the ensuing annual general meeting, Biocon said. For FY26, consolidated net profit was at Rs 368.8 crore, down from Rs 1,4